B. Riley Wealth Advisors Inc. Decreases Stock Position in Boston Scientific Co. (NYSE:BSX)

B. Riley Wealth Advisors Inc. lessened its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 30.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,838 shares of the medical equipment provider's stock after selling 4,715 shares during the quarter. B. Riley Wealth Advisors Inc.'s holdings in Boston Scientific were worth $968,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of BSX. Brighton Jones LLC increased its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares in the last quarter. PFG Investments LLC increased its holdings in Boston Scientific by 1.6% in the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after buying an additional 125 shares in the last quarter. Blue Trust Inc. increased its holdings in Boston Scientific by 43.7% in the 4th quarter. Blue Trust Inc. now owns 15,077 shares of the medical equipment provider's stock worth $1,263,000 after buying an additional 4,585 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Boston Scientific in the 4th quarter worth about $33,074,000. Finally, Pacer Advisors Inc. increased its holdings in Boston Scientific by 21.8% in the 4th quarter. Pacer Advisors Inc. now owns 138,057 shares of the medical equipment provider's stock worth $12,331,000 after buying an additional 24,754 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Argus set a $130.00 price objective on Boston Scientific in a report on Tuesday, February 18th. Robert W. Baird lifted their price objective on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Citigroup reiterated a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Stifel Nicolaus boosted their price target on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a research note on Wednesday. Twenty-one equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $116.00.

Insider Buying and Selling

In other news, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares of the company's stock, valued at $1,955,420.70. This represents a 19.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total value of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares in the company, valued at $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 191,155 shares of company stock valued at $19,556,047. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

NYSE BSX traded up $0.58 during trading hours on Friday, reaching $105.08. The company's stock had a trading volume of 10,524,691 shares, compared to its average volume of 6,427,290. The firm's 50-day moving average price is $100.29 and its 200-day moving average price is $97.88. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a market capitalization of $155.46 billion, a price-to-earnings ratio of 84.06, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the previous year, the firm earned $0.56 EPS. The firm's revenue was up 20.9% compared to the same quarter last year. On average, equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.